Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253394 · ClinicalTrials.gov registry record · Phase 4
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT02253394 is a Phase 4 study that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 2 participants.
The verdict
NCT02253394, a Phase 4 study, was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity. We also want to find out if spironolactone and ambrisentan effect the cardiac output (amount of blood the heart pumps every minute), right ventricle function and quality of life.
Interventions
- DRUG Ambrisentan plus Spironolactone
- DRUG Ambrisentan plus Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253394
The ClinicalTrials.gov registry entry for NCT02253394 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ambrisentan plus Spironolactone is the first listed.
NCT02253394 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02253394 about?
NCT02253394 is a clinical study titled "The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study". The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity. We also want to find out if spironolactone and ambrisentan effect the cardiac output (amount of blood the heart pumps every minute), right ventri...
What is the current status of trial NCT02253394?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2015-09. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02253394?
The interventions under investigation include: Ambrisentan plus Spironolactone (DRUG), Ambrisentan plus Placebo (DRUG).
Who is sponsoring clinical trial NCT02253394?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.